Literature DB >> 21499927

Nanoparticles targeting HLA-G for gene therapy in cancer.

Ines Zidi1, Nidhal Ben Amor.   

Abstract

Cancer cells are aided by immune-tolerant functions of HLA-G to escape the immune surveillance. In general, cancer cells can express membranous HLA-G, secrete soluble HLA-G, produce HLA-G positive exosomes, and can be subjected to proteolytic cleavage by matrix metalloproteinases releasing shedding HLA-G1 in stressful conditions. Thus, the downregulation of HLA-G either in transcripts or proteins may affect positively cancer therapy. The aim of this study was to examine the molecular nanoparticles targeting HLA-G. Special focus was accorded to RNA interference particles. Although numerous studies have reported the importance of HLA-G gene expression modulation by nanoparticles, no studies have investigated clinically their efficiency in this modulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499927     DOI: 10.1007/s12032-011-9942-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  59 in total

Review 1.  Efficient and targeted delivery of siRNA in vivo.

Authors:  Min Suk Shim; Young Jik Kwon
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

2.  Regulating MHC expression for cellular therapeutics.

Authors:  Constança Figueiredo; Peter A Horn; Rainer Blasczyk; Axel Seltsam
Journal:  Transfusion       Date:  2007-01       Impact factor: 3.157

3.  Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response.

Authors:  Dan-dan Dong; Hong Yang; Ke Li; Gang Xu; Lin-hong Song; Xiao-li Fan; Xin-lian Jiang; Shang-mian Yie
Journal:  Reprod Sci       Date:  2010-05-05       Impact factor: 3.060

4.  Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine.

Authors:  Wei Hua Yan; Ai Fen Lin; Chien Chung Chang; Soldano Ferrone
Journal:  Cell Res       Date:  2005-07       Impact factor: 25.617

Review 5.  siRNA applications in nanomedicine.

Authors:  Talar Tokatlian; Tatiana Segura
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 May-Jun

6.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Martina Skrede; Hiep Phuc Dong; Søren Nielsen; Michael T McMaster; Jahn M Nesland; Ie-Ming Shih; Ben Davidson
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

Review 7.  Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.

Authors:  Nathalie Rouas-Freiss; Philippe Moreau; Catherine Menier; Joël LeMaoult; Edgardo D Carosella
Journal:  Semin Cancer Biol       Date:  2007-07-17       Impact factor: 15.707

8.  Tolerance versus immune response -- microRNAs as important elements in the regulation of the HLA-G gene expression.

Authors:  T D Veit; J A B Chies
Journal:  Transpl Immunol       Date:  2008-11-25       Impact factor: 1.708

Review 9.  Current strategies in cancer gene therapy.

Authors:  Anas El-Aneed
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

10.  Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors.

Authors:  Laura Menendez; L DeEtte Walker; Lilya V Matyunina; Kimberly A Totten; Benedict B Benigno; John F McDonald
Journal:  Mol Cancer       Date:  2008-05-22       Impact factor: 27.401

View more
  3 in total

Review 1.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

Review 2.  New Insights Into the Role of Qa-2 and HLA-G Non-classical MHC-I Complexes in Malignancy.

Authors:  Istéfani L da Silva; Lucía Montero-Montero; Enio Ferreira; Miguel Quintanilla
Journal:  Front Immunol       Date:  2018-12-06       Impact factor: 7.561

Review 3.  Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine.

Authors:  Danijela Koppers-Lalic; Marye M Hogenboom; Jaap M Middeldorp; D Michiel Pegtel
Journal:  Adv Drug Deliv Rev       Date:  2012-07-20       Impact factor: 15.470

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.